10 Affordable Biotech Stocks to Buy Right Now

7. Palvella Therapeutics Inc. (NASDAQ:PVLA)

Palvella Therapeutics Inc. (NASDAQ:PVLA) is one of the 10 affordable biotech stocks to buy right now.

On June 29, Palvella Therapeutics Inc. (NASDAQ:PVLA) disclosed that it filed the initial module of its New Drug Application with the FDA for approval of QTORIN 3.9% rapamycin anhydrous gel. QTORIN is used to treat microcystic lymphatic malformations.

The company plans to file the remaining modules and conclude the NDA application process during the latter half of 2026. The company highlighted that QTORIN rapamycin has attained FDA designations for Orphan Drug, Fast Track designations, and Breakthrough Therapy. The company is also speeding up U.S. launch preparation for a possible independent commercial launch in the early half of 2027, subject to approval.

Earlier on June 22, the company revealed that the FDA had provided a rolling review for QTORIN rapamycin’s New Drug Application. Palvella Founder and CEO, Wes Kaupinen, highlighted that the company plans to use the Breakthrough Therapy, the benefits of rolling review, and Fast Track designations to facilitate an efficient route toward achieving FDA approval. He further stated:

“Following the positive Phase 3 SELVA results, our focus is clear: move with urgency to advance QTORIN rapamycin as the potential first FDA-approved therapy for patients and families affected by microcystic LMs, a serious, lifelong rare disease with no approved treatment options.”

Palvella Therapeutics Inc. (NASDAQ:PVLA) is engaged in the development and marketing of innovative medical technologies and treatments for people suffering from severe and uncommon genetic skin diseases. QTORIN rapamycin, which is the company’s leading product, is currently undergoing Phase 3 trials for microcystic lymphatic malformations and Phase 2 trials for cutaneous venous malformations.